Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of “Moderate Buy” from Analysts

Cogent Biosciences, Inc. (NASDAQ:COGT) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $43.7273.

A number of research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, April 10th. Wedbush reissued an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a research report on Friday, May 29th. HC Wainwright increased their price target on shares of Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Jefferies Financial Group began coverage on shares of Cogent Biosciences in a research report on Monday, March 16th. They issued a “buy” rating and a $55.00 price target for the company.

Cogent Biosciences Stock Up 0.3%

Shares of COGT opened at $38.12 on Tuesday. The company has a 50-day simple moving average of $34.48 and a 200-day simple moving average of $36.30. The firm has a market capitalization of $6.51 billion, a P/E ratio of -17.56 and a beta of 0.34. The company has a debt-to-equity ratio of 0.41, a quick ratio of 15.14 and a current ratio of 15.14. Cogent Biosciences has a 52 week low of $7.07 and a 52 week high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) EPS for the quarter, meeting analysts’ consensus estimates of ($0.53). On average, equities research analysts expect that Cogent Biosciences will post -2.26 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Fairmount Funds Management LLC raised its stake in shares of Cogent Biosciences by 44.6% in the third quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company’s stock valued at $129,289,000 after acquiring an additional 2,777,777 shares during the last quarter. Pier Capital LLC bought a new position in shares of Cogent Biosciences in the fourth quarter valued at approximately $1,643,000. Vanguard Group Inc. raised its stake in shares of Cogent Biosciences by 48.4% in the fourth quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company’s stock valued at $408,989,000 after acquiring an additional 3,756,664 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Cogent Biosciences by 710.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 112,476 shares of the technology company’s stock valued at $4,232,000 after acquiring an additional 98,602 shares during the last quarter. Finally, Cinctive Capital Management LP bought a new position in shares of Cogent Biosciences in the third quarter valued at approximately $1,595,000.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.